About one in six women of reproductive age face difficulties in conceiving or carrying a pregnancy to term. Although there has been a global increase in the use of assisted reproductive technologies ...
(Beyond Pesticides, October 8, 2024) A comprehensive literature review in Endocrines, published in September, amasses hundreds of studies on endocrine-disrupting chemicals (EDCs) that showcase adverse ...
Neoadjuvant dynamic marker-adjusted personalized therapy comparing trastuzumab-deruxtecan versus pacli-/docetaxel + carboplatin + trastuzumab + pertuzumab in HER2+ early breast cancer: ...
The addition of Ibrance to endocrine therapy was not associated with preventing disease recurrence in patients with hormone receptor (HR)–positive, human epidermal growth factor receptor 2 ...
A011801 (CompassHER2 RD): Postneoadjuvant T-DM1 + tucatinib/placebo in patients with residual HER2-positive invasive breast cancer. Background: Hormone receptor positive (HR+), human epidermal growth ...
(Beyond Pesticides, January 9, 2025) In a Frontiers in Public Health review article, researchers report on the wide body of science connecting adverse effects to female reproductive system, such as ...
In a previous post, I discussed the connection between the mind and the skin. In that article, I called for patients and clinicians to become more aware of the relationship between cutaneous and ...
A popular class of therapies for treating diabetes and obesity may also have the potential to treat alcohol and drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback